Earnings results for Bio-Rad Laboratories (NYSE:BIO)
Bio-Rad Laboratories, Inc. is expected* to report earnings on 02/11/2021 after market close. The report will be for the fiscal Quarter ending Dec 2020. According to Zacks Investment Research, based on 1 analysts’ forecasts, the consensus EPS forecast for the quarter is $3.1. The reported EPS for the same quarter last year was $2.32.
Analyst Opinion on Bio-Rad Laboratories (NYSE:BIO)
4 Wall Street analysts have issued ratings and price targets for Bio-Rad Laboratories in the last 12 months. Their average twelve-month price target is $621.00, predicting that the stock has a possible downside of 1.73%. The high price target for BIO is $725.00 and the low price target for BIO is $430.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of “Buy.”
Bio-Rad Laboratories has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $621.00, Bio-Rad Laboratories has a forecasted downside of 1.7% from its current price of $631.92. Bio-Rad Laboratories has only been the subject of 1 research reports in the past 90 days.
Dividend Strength: Bio-Rad Laboratories (NYSE:BIO)
Bio-Rad Laboratories does not currently pay a dividend. Bio-Rad Laboratories does not have a long track record of dividend growth.
Insiders buying/selling: Bio-Rad Laboratories (NYSE:BIO)
In the past three months, Bio-Rad Laboratories insiders have sold more of their company’s stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $217,171.00 in company stock. Only 27.50% of the stock of Bio-Rad Laboratories is held by insiders. 63.03% of the stock of Bio-Rad Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Earnings and Valuation of Bio-Rad Laboratories (NYSE:BIO
Earnings for Bio-Rad Laboratories are expected to grow by 6.14% in the coming year, from $9.61 to $10.20 per share. The P/E ratio of Bio-Rad Laboratories is 5.41, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 23.86. The P/E ratio of Bio-Rad Laboratories is 5.41, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 38.01. Bio-Rad Laboratories has a P/B Ratio of 3.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
More latest stories: here